Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.
Gao Y, Paxinos E, Galovich J, Troyer R, Baird H, Abreha M, Kityo C, Mugyenyi P, Petropoulos C, Arts EJ. Gao Y, et al. Among authors: galovich j. J Virol. 2004 May;78(10):5390-401. doi: 10.1128/jvi.78.10.5390-5401.2004. J Virol. 2004. PMID: 15113918 Free PMC article.
Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection.
Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, Boden D, Galovich J, Tenner-Racz K, Racz P, Carrington M, Petropoulos C, Katinger H, Markowitz M. Mehandru S, et al. Among authors: galovich j. J Virol. 2007 Oct;81(20):11016-31. doi: 10.1128/JVI.01340-07. Epub 2007 Aug 8. J Virol. 2007. PMID: 17686878 Free PMC article. Clinical Trial.
Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.
Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, Sinclair E, Hunt P, McCune JM, Martin JN, Petropoulos CJ, Hecht FM. Deeks SG, et al. Among authors: galovich j. J Virol. 2006 Jun;80(12):6155-64. doi: 10.1128/JVI.00093-06. J Virol. 2006. PMID: 16731954 Free PMC article.
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.
Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos CJ, Little SJ, Richman DD. Frost SD, et al. Among authors: galovich j. Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18514-9. doi: 10.1073/pnas.0504658102. Epub 2005 Dec 9. Proc Natl Acad Sci U S A. 2005. PMID: 16339909 Free PMC article.